Episodes

  • ATTR-CM: What do we know about blood levels of the TTR protein? A discussion with experts

    ATTR-CM: What do we know about blood levels of the TTR protein? A discussion with experts
    Feb 27 2026
    Proteins are biological machines in living things. A protein called transthyretin, abbreviated as “TTR”’, normally flows in blood to move certain chemicals from one place to another. For normal function, 4 copies of TTR need to be folded together in a specific way. If TTR becomes unfolded or folds the wrong way, it will clump with other TTR proteins. These clumps stick to organ tissues and build up over time. As the sticky clumps grow, they prevent the organs from working properly. When this happens in the heart, it can lead to a weakened heart muscle and eventually death. Acoramidis is a drug that keeps the 4 copies of TTR together and folded correctly. In this medical study, doctors looked at the amount of TTR in the blood of 557 people with misfolded TTR. They found treatment with acoramidis quickly increased the amount of TTR in blood, which lowered the risk of death by more than one-fourth.

    Hosted on Acast. See acast.com/privacy for more information.
    Show More Show Less
    8 mins
  • Shifting Treatment Paradigm in Multiple Myeloma: A Podcast Integrating ASH 2025 Data with Patient and Physician Perspectives

    Shifting Treatment Paradigm in Multiple Myeloma: A Podcast Integrating ASH 2025 Data with Patient and Physician Perspectives
    Mar 26 2026

    In this plain language podcast, highlights from the 67th American Society of Hematology Annual Meeting and Exposition (ASH 2025) are discussed, with insights from the perspective of an expert patient and physician experienced in the field of multiple myeloma (MM). This podcast aims to enhance the communication and understanding of complex scientific data on MM among a broad audience, including both specialists and non-specialists, and help guide the partnership between patients and clinicians in making informed treatment decisions.


    Three key topics are covered by the podcast: Emerging evidence supporting a shift to earlier use of T-cell directed therapies facilitating an earlier immune response in MM patients; evidence for proactive strategies to optimize the patient outcomes and experience with T-cell-redirecting therapies; and an overview of novel T-cell-directed regimens entering the field for typically difficult-to-treat relapsed/refractory multiple myeloma (RRMM).



    Journal- Therapeutic Advances in Hematology

    Article title: Shifting Treatment Paradigm in Multiple Myeloma: A Podcast Integrating ASH 2025 Data with Patient and Physician Perspectives

    Corresponding author: Rahul Banerjee

    Hosted on Acast. See acast.com/privacy for more information.
    Show More Show Less
    43 mins